Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Brokerages

Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have covered the stock in the last year is $9.30.

A number of equities analysts have issued reports on MD shares. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 target price for the company in a research report on Friday, June 7th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research report on Friday, August 9th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th.

Insiders Place Their Bets

In other news, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares in the company, valued at $1,943,272.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO C Marc Richards sold 32,562 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,100 shares of company stock valued at $701,889. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP raised its position in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the period. Invenomic Capital Management LP increased its position in Pediatrix Medical Group by 93.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after acquiring an additional 664,955 shares during the period. Dana Investment Advisors Inc. increased its position in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the period. Boston Partners increased its position in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares during the period. Finally, Clark Estates Inc. NY bought a new position in Pediatrix Medical Group during the fourth quarter worth $3,302,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Trading Down 2.9 %

Shares of Pediatrix Medical Group stock opened at $10.56 on Friday. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $13.01. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market capitalization of $888.59 million, a P/E ratio of -12.42, a PEG ratio of 1.68 and a beta of 1.56. The company’s fifty day moving average is $9.71 and its two-hundred day moving average is $8.82.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. The business had revenue of $504.30 million for the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.37 earnings per share. Analysts forecast that Pediatrix Medical Group will post 1.18 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.